Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits....
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/4543861 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553760763674624 |
|---|---|
| author | Renliang Yi Baoxin Chen Peng Duan Chanjiao Zheng Huanyu Shen Qun Liu Chen Yuan Weilin Ou Zhiheng Zhou |
| author_facet | Renliang Yi Baoxin Chen Peng Duan Chanjiao Zheng Huanyu Shen Qun Liu Chen Yuan Weilin Ou Zhiheng Zhou |
| author_sort | Renliang Yi |
| collection | DOAJ |
| description | New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p>0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p>0.05). |
| format | Article |
| id | doaj-art-7dd266e1b8204344a40ce8e6c262b8c6 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7dd266e1b8204344a40ce8e6c262b8c62025-02-03T05:53:19ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/45438614543861Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-AnalysisRenliang Yi0Baoxin Chen1Peng Duan2Chanjiao Zheng3Huanyu Shen4Qun Liu5Chen Yuan6Weilin Ou7Zhiheng Zhou8Guangzhou Hospital of Guangzhou Military Region, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaSchool of Public Health, Guangzhou Medical University, Guangzhou, ChinaDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USANew treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p>0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p>0.05).http://dx.doi.org/10.1155/2016/4543861 |
| spellingShingle | Renliang Yi Baoxin Chen Peng Duan Chanjiao Zheng Huanyu Shen Qun Liu Chen Yuan Weilin Ou Zhiheng Zhou Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis Journal of Immunology Research |
| title | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis |
| title_full | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis |
| title_fullStr | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis |
| title_full_unstemmed | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis |
| title_short | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis |
| title_sort | sipuleucel t and androgen receptor directed therapy for castration resistant prostate cancer a meta analysis |
| url | http://dx.doi.org/10.1155/2016/4543861 |
| work_keys_str_mv | AT renliangyi sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT baoxinchen sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT pengduan sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT chanjiaozheng sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT huanyushen sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT qunliu sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT chenyuan sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT weilinou sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis AT zhihengzhou sipuleuceltandandrogenreceptordirectedtherapyforcastrationresistantprostatecancerametaanalysis |